Evidence map›Paper›PMID 31260444›Full record

ArticlePLoS neglected tropical diseases2019

Economic performance and cost-effectiveness of using a DEC-salt social enterprise for eliminating the major neglected tropical disease, lymphatic filariasis.

Swarnali Sharma, Morgan E Smith, James Reimer, David B O'Brien, Jean M Brissau, Marie C Donahue, Clarence E Carter, Edwin Michael

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Swarnali SharmaDepartment of Biological Sciences, University of Notre Dame, Galvin Life Science Center, Notre Dame, IN, United States of America.
Morgan E SmithDepartment of Biological Sciences, University of Notre Dame, Galvin Life Science Center, Notre Dame, IN, United States of America.
James ReimerGrosse Pointe Park, MI, United States of America.
David B O'BrienChattahoochee Hills, GA United States of America.
Jean M BrissauCollege of Science, University of Notre Dame, Notre Dame, IN, United States of America.
Marie C DonahueEck Institute of Global Health, University of Notre Dame, Notre Dame, IN, United States of America.
Clarence E CarterCollege of Science, University of Notre Dame, Notre Dame, IN, United States of America.
Edwin MichaelDepartment of Biological Sciences, University of Notre Dame, Galvin Life Science Center, Notre Dame, IN, United States of America.ORCID 0000-0002-9473-4245
University of Notre Dame · USChattahoochee Technical College · USGrosse Pointe Public Library · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSalt fortified with the drug, diethylcarbamazine (DEC), and introduced into a competitive market has the potential to overcome the obstacles associated with tablet-based Lymphatic Filariasis (LF) elimination programs. Questions remain, however, regarding the economic viability, production capacity, and effectiveness of this strategy as a sustainable means to bring about LF elimination in resource poor settings. METHODOLOGY AND PRINCIPAL

findingsWe evaluated the performance and effectiveness of a novel social enterprise-based approach developed and tested in Léogâne, Haiti, as a strategy to sustainably and cost-efficiently distribute DEC-medicated salt into a competitive market at quantities sufficient to bring about the elimination of LF. We undertook a cost-revenue analysis to evaluate the production capability and financial feasibility of the developed DEC salt social enterprise, and a modeling study centered on applying a dynamic mathematical model localized to reflect local LF transmission dynamics to evaluate the cost-effectiveness of using this intervention versus standard annual Mass Drug Administration (MDA) for eliminating LF in Léogâne. We show that the salt enterprise because of its mixed product business strategy may have already reached the production capacity for delivering sufficient quantities of edible DEC-medicated salt to bring about LF transmission in the Léogâne study setting. Due to increasing revenues obtained from the sale of DEC salt over time, expansion of its delivery in the population, and greater cumulative impact on the survival of worms leading to shorter timelines to extinction, this strategy could also represent a significantly more cost-effective option than annual DEC tablet-based MDA for accomplishing LF elimination. SIGNIFICANCE: A social enterprise approach can offer an innovative market-based strategy by which edible salt fortified with DEC could be distributed to communities both on a financially sustainable basis and at sufficient quantity to eliminate LF. Deployment of similarly fashioned intervention strategies would improve current efforts to successfully accomplish the goal of LF elimination, particularly in difficult-to-control settings.

Indexed as

Administration, OralCost-Benefit AnalysisDiethylcarbamazineDisease EradicationElephantiasis, FilarialFilaricidesHaitiHealth ResourcesHumansMass Drug AdministrationModels, TheoreticalNeglected DiseasesSocial MedicineSodium Chloride, DietaryDiethylcarbamazineFilaricidesSodium Chloride, Dietary

Identifiers

PMID31260444
PMCPMC6625731
OpenAlexW2955891844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.